Mercer International Inc. (MERC)

Taken together, the convergence ... combination in bladder cancer, and a solid Q1 earnings beat with raised guidance has given investors multiple reasons to re-rate the stock higher today. The significant positive movement in Merck’s share price is largely driven by favorable ...

Entities tied to Peter R. Kellogg bought 700,000 Mercer shares around $0.95–$0.97, lifting Harco’s indirect stake to 1,957,000 shares and updating broad indirect holdings.

Investing.com - Fitch Ratings downgraded Mercer International Inc.’s Long-Term Issuer Default Rating to ’CCC-’ from ’B-’ today and lowered the issue ratings of the senior unsecured notes to ’CCC’ with a Recovery Rating of ’RR3’ from ’B-’/’RR4’. The downgrade reflects ...

Merck has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6.8%. The stock now trades at $113.99, marking a 20% gain. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Stock NewsBusinessExecutive TradesInsights & GuidesInvestingEducationMarketMarket NewsTechnical IndicatorsTechnology ... Merck & Co., Inc. (MRK) will report first-quarter earnings on April 30, 2026. Analysts expect the pharmaceutical giant to post a loss of $1.51 per share with revenue of $15.85 ...